January 31, 2014
Sanofi K.K. is demanding that Novartis Pharma pay to the tune of US$416 million over the termination of their copromotion agreement for the dipeptidyl peptidase-4 (DPP-4) inhibitor Equa (vildagliptin) in Japan, it has been learned. An arbitration proceeding was initiated...read more